The Epstein ± Barr Virus (EBV) LMP1 protein is frequently expressed in nasopharyngeal carcinoma and is essential for the transforming eects of EBV. Analysis of LMP1 genes isolated from tumor biopsies has revealed considerable sequence variation including deletion of amino acids 343 ± 352. Several studies have suggested that this sequence variation could enhance the transforming potential of LMP1. LMP1 has profound eects on cellular gene expression mediated in part through activation of the NF-kB transcription factor. In addition, LMP1 engages the TRAF signaling pathway resulting in the induction of EGFR expression. In this study, the LMP1 proteins derived from the laboratory strain B95-8 and the NPC strain C15 were analysed for their ability to activate NF-kB and also to induce expression of the EGFR. The data suggest that the C15-LMP1 protein activates NF-kB more eciently and induces higher levels of the EGFR. Analysis of chimeric LMP1 proteins indicates that the amino terminal 181 amino acids of C15-LMP1 confer this increased signaling capability, and that deletion of amino acids 343 ± 352 does not aect these properties. Finally, these data provide evidence that ®ve amino acid changes within the transmembrane domain in the C15-LMP1 protein lead to enhanced NF-kB activation and EGFR induction.
Introduction
The Epstein ± Barr virus (EBV), a member of the human herpesvirus family, infects the majority of the human population and establishes a life-long infection. Although viral infection is usually latent and asymptomatic, several human malignancies are strongly associated with EBV. These include post-transplant lymphoma (PTL), Hodgkin's lymphoma (HL), and a subset of Burkitt's lymphoma (BL) Kie, 1996; Rickinson and Kie, 1996) . The virus is also causally associated with the human epithelial malignancy, nasopharyngeal carcinoma (NPC) (RaabTraub and Flynn, 1986; Raab-Traub et al., 1987; Raab-Traub, 1992; Rajadurai et al., 1995) . Latent Membrane Protein 1 (LMP1) is frequently expressed in EBV associated malignancies and is expressed in all examples of preinvasive epithelial lesions, suggesting that expression of this protein may be important for carcinogenesis (Fahraeus et al., 1988; Young et al., 1988; Gilligan et al., 1990; Rajadurai et al., 1995) .
The transforming eects of LMP1 are likely due to its profound eects on cellular gene expression. In Blymphocytes, LMP1 induces the expression of the cellular activation antigens CD23 and CD40, as well as the adhesion molecules ICAM-1 and LFA-3 (Wang et al., 1990; Huen et al., 1995) . LMP1 also induces the expression of the anti-apoptotic bcl-2 and A20 molecules (Henderson et al., 1991; Laherty et al., 1992) . In epithelial cells LMP1 induces expression of the epidermal growth factor receptor (EGFR) and A20 genes (Miller et al., 1995; Fries et al., 1996) .
Recent experiments have begun to de®ne regions of LMP1 which are important for its eect on the activation of signal transduction pathways and cellular gene expression. The LMP1 protein consists of a 24 amino acid cytoplasmic domain at the amino terminus of the protein, a membrane spanning hydrophobic domain consisting of six transmembrane segments connected by short turns between amino acids 25 and 187, followed by a 200 amino acid cytoplasmic domain at the carboxy terminus. The amino terminal cytoplasmic domain is structurally important for proper insertion of the LMP1 protein into the plasma membrane (Izumi et al., 1994) . The membrane spanning hydrophobic domain of LMP1 is also essential for function since mutants deleted for this domain are unable to properly cluster in the plasma membrane or initiate signaling events (Liebowitz et al., 1992; Huen et al., 1995; Miller et al., 1997) . The cytoplasmic carboxy terminal region contains two signaling domains that are essential for directly mediating the changes in cellular gene expression described above. The distal domain located between amino acids 352 and 386 is responsible for *75% of the NF-kB activity while the proximal domain located between amino acids 187 and 231 is responsible for *25% of the NF-kB activity (Huen et al., 1995; Mitchell and Sugden, 1995; Miller et al., 1997) . The proximal domain interacts with the TNF-a receptor associated factors (TRAFs) which in turn activate NFkB (Mosialos et al., 1995; Kaye et al., 1996; Devergne et al., 1997) . The proximal domain (TRAF domain) also induces expression of the EGFR through a pathway distinct from NF-kB activation alone since LMP1 mutants which lack the proximal domain and retain the distal domain activate NF-kB but do not induce EGFR expression (Miller et al., 1997) .
Although EBV is ubiquitous in the human population, NPC develops with high incidence in Asian and Eskimo populations, and with elevated incidence in Mediterranean populations. This ®nding suggests that additional factors such as environmental co-factors and/or EBV strain variation could contribute to the development of NPC. Based on sequence variation within the Epstein ± Barr virus nuclear antigens (EBNAs), two major subtypes of EBV have been de®ned (type 1 and type 2) (Rowe et al., 1989; Sample et al., 1990) . Sequence variation within EBNA2 strongly aects transformation in vitro. The type 2 EBNA2 gene is much less transforming than its type 1 counterpart, although both types are detected in B-cell lymphomas associated with EBV and in NPC (Rickinson et al., 1987; Abdel-Hamid et al., 1992) . LMP1 genes do not vary according to the type 1 and type 2 designation, however, sequence analysis of LMP1 genes from tumor isolates indicates that EBV strains dier considerably in their LMP1 sequences (Miller et al., 1994; Sample et al., 1994) . Strains are marked by consistent amino acid changes detected throughout the protein, and by the absence or presence of amino acids 343 ± 352 within the carboxy terminus (Hu et al., 1991; Knecht et al., 1993 Knecht et al., , 1995 Knecht et al., , 1996 Miller et al., 1994) .
The contribution of sequence variation to the function of the LMP1 protein is just beginning to be elucidated. The CAO-LMP1 and 1510-LMP1 genes isolated from Asian NPC tumors have multiple amino acid changes and are deleted for amino acids 343 ± 352 (Hu et al., 1991; Chen et al., 1992) . Expression of the CAO-LMP1 and 1510-LMP1 proteins in rodent ®broblasts have higher transforming potential than the LMP1 protein derived from the B95-8 laboratory strain. B95-8 is an EBV strain obtained from an infectious mononucleosis patient and the LMP1 gene derived from this isolate will be referred to as B95-LMP1. A recent study demonstrated that deletion of amino acids 343 ± 352 from the carboxy terminus in the B95 derived background increased its transforming potential in rodent ®broblasts. This dierence in transforming potential may indicate that LMP1 genes deleted for these amino acids could have increased pathogenesis in vivo and may be more likely to cause malignancies like NPC (Li et al., 1996) . The CAO-LMP1 gene has also been shown to enhance LMP1 tumor growth in nude mice (Hu et al., 1993) . In addition, the NPC derived CAO-LMP1 gene was nonimmunogenic in comparison with the B95-LMP1 (Trivedi et al., 1994) .
Cell lines derived from NPC tumors cannot be established and only rarely can NPC tumors be passaged as xenografts in nude mice . Therefore, the nude mouse passaged NPC tumor C15 has emerged as the prototypical example of this tumor type. C15 is an NPC which developed in a 13 year old Caucasian Mediterranean female. Analysis of the C15 tumor has led to a further understanding of EBV gene expression in NPC and has also begun to indicate some of the cellular changes that are associated with development of NPC (Gilligan et al., 1990 (Gilligan et al., , 1991 Smith and Grin, 1991; Busson et al., 1992a, b) .
The purpose of this study was to compare the abilities of the standard laboratory derived B95-LMP1 and the NPC derived C15-LMP1 proteins to activate NF-kB and to activate TRAF signaling pathways resulting in the induction of EGFR expression. Identical to the CAO-LMP1 and 1510-LMP1 isolates described above, the C15-LMP1 gene is also deleted for amino acids 343 ± 352 enabling an analysis of the eect of this deletion on NF-kB activation and EGFR induction (Hu et al., 1991; Miller et al., 1994) . The data presented here indicate that the NPC derived C15-LMP1 protein has higher NF-kB activation potential, and is capable of inducing higher levels of EGFR expression compared to the B95-LMP1 protein.
Furthermore, the use of chimeric LMP1 proteins containing various portions of the (B95-LMP1 or C15-LMP1) genes, indicates that sequence changes in the hydrophobic transmembrane domains of the C15-LMP1 protein confer the increased signaling detected with this isolate. These studies also reveal that sequence changes in the carboxy terminal region, including deletion of amino acids 343 ± 352, do not aect NF-kB activation or EGFR induction. Finally, the data presented in this study indicate that the enhanced transforming potential demonstrated in rodent ®broblasts with NPC-derived LMP1 proteins deleted for amino acids 343 ± 352 is not due to enhanced NF-kB activation or EGFR induction.
Results

Alterations in C15-LMP1 amino acid sequence
Sequence analysis of LMP1 cDNAs derived from the C15 NPC tumor indicates that several dierences are present between this viral variant and the B95 prototype strain (Gilligan et al., 1990; Miller et al., 1994) . Although there are no dierences within the amino terminal cytoplasmic domain of C15-LMP1, there are ®ve changes within the hydrophobic transmembrane domain (Figure 1 ). Interestingly, the methionine (amino acid 129) which is used to initiate Figure 1 Alterations in the LMP1 amino acid sequence derived from the C15 NPC tumor. The C15 derived LMP1 protein contains several amino acid changes in both the transmembrane domains and the carboxy terminal region with respect to the B95-LMP1 protein. R1(Pos-3) refers to the third amino acid in repeat number 1. The carboxy terminal region is also deleted for amino acids 276 ± 280 (HDPLP) in the third repeat and contains an extra copy of the repeat between amino acids 298 and 299. C15 is also deleted for amino acids 343 ± 352; a deletion of unknown consequence which is commonly found in LMP1 translation of a truncated LMP1 protein in latently infected cells is mutated to an isoleucine in the C15 LMP1 sequence (Wang et al., 1988) .
Within the long cytoplasmic domain of C15-LMP1, two amino acid changes are located in the regions shown to be independently important for signaling events. Although there are no changes in the TRAF interaction motif (amino acids 204 ± 208) there is a conserved serine to threonine change at amino acid 229 within the TRAF interaction domain. A second change, serine to alanine at amino acid 366, is located within the distal NF-kB activation domain. Four additional mutations in the carboxy terminus are located outside of the described signaling domains and although the eect of these mutations will be presented, they are unlikely to aect the function of the protein.
Several deletions and insertions were detected in the C15 sequence. LMP1 contains a variable number of a repeating 11 amino acid sequence (DNGPQ-DPDNTD). The function of this repeating sequence is unknown, but it does not reside within either the proximal TRAF interaction domain (amino acids 187 ± 231), or the distal NF-kB activation domain (amino acids 352 ± 386). The B95-LMP1 has four copies of this repeating sequence, while C15-LMP1 has an extra copy of the repeats. In addition, the B95-LMP1 has a ®ve amino acid insertion (HDPLP) within the third repeat that is not present in the C15-LMP1 (amino acids 276 ± 280 of the B95 sequence). Interestingly, the ®rst repeat in the C15 protein contains a conserved glycine to alanine change at amino acid position three of the repeat, while repeats 2 ± 5 contain non-conserved aspartic acid to glycine changes at amino acid position 6 of the repeats. The C15-LMP1 isolate is also deleted for amino acids 343 ± 352; a deletion frequently found within the LMP1 gene in Chinese and other NPC isolates regardless of geographic location (Hu et al., 1991; Chen et al., 1992; Knecht et al., 1993 Knecht et al., , 1995 Knecht et al., , 1996 Miller et al., 1994) .
Construction of C15-LMP1 and chimeric expression constructs
To analyse the eects of amino acid changes in the C15-LMP1 protein on the activation of NF-kB as well as the induction of the EGFR, expression constructs were prepared using cDNAs cloned from a C15 cDNA library ( Figure 2 ). Two overlapping cDNAs were obtained which encompassed the entire LMP1 open reading frame (ORF) as well as 3' and 5' untranslated regions (UTRs). The 3' UTR was identical to the B95 derived cDNA and the 5' UTR is extended by 200 bp. The cDNAs were fused at a unique BsaBI site in the cDNA to create a full length LMP1 cDNA derived from the C15 NPC tumor. The full length C15-LMP1 cDNA was cloned into the eukaryotic expression vector pcDNA3. To analyse the eects of sequence changes within either the amino terminus or carboxy terminus on LMP1 function, several LMP1 chimeras were constructed containing portions of either the C15 or B95 derived LMP1 genes ( Figure 2 ). Since the LMP1 sequence contains a unique BsaBI site within the ORF, the chimeric LMP1 expression plasmids were fused at this site. The BsaBI site is located at amino acid 181 of the protein, therefore chimeras containing amino acids 1 ± 181 of B95-LMP1 and amino acids 182 ± 386 of C15-LMP1 (B95/C15) or amino acids 1 ± 181 of C15-LMP1 and amino acids 182 ± 386 of B95-LMP1 (C15/B95) were constructed. The 181 amino terminal amino acids from the C15-LMP1 protein contain ®ve substitutions as described in Figure 1 . The carboxy terminal region of LMP1 (amino acids 187 ± 386) contains the important sequences for signaling events. The amino terminal region (amino acids 1 ± 186) contains the amino terminal cytoplasmic and transmembrane domains which are important for proper membrane localization and clustering. Any dierences found between C15-LMP1 and B95-LMP1 could therefore be localized to either region since the chimeras were fused at amino acid 181.
Expression of the C15-LMP1 and B95/C15 chimeric proteins
To evaluate expression of the newly derived LMP1 constructs, C33A cells were transfected with each construct and the cells were analysed for LMP1 expression by immunoblot (Figure 3 ). Immunoblots were probed in parallel with the LMP1 speci®c CS1-4 and S12 monoclonal antibodies. Immunoblot analyses indicate that the C15 derived LMP1 as well as the C15/ B95 chimeric proteins are expressed at approximately equal levels (Figure 3) . Protein extracts from the EBV positive LMP1 expressing CB5 (B95) lymphoblastoid cell line (LCL) established by transformation of human lymphocytes with the B95-8 EBV strain were used as a positive control. The CS1-4 antibody recognized all of the LMP1 proteins, while the S12 antibody only recognized the proteins which retained the B95 cytoplasmic C-terminus (B95 and C15/B95). Previous studies indicate that the S12 antibody recognizes the B95 derived LMP1 protein, but not the C15 derived (Young et al., 1988) . The CS1-4 antibody, in contrast, recognized LMP1 proteins present in both B95 and C15 infected cells (Young et al., 1988) . Sequence analyses of LMP1 from various isolates which are recognized by the S12 monoclonal antibody compared to isolates that are not recognized by S12 have not revealed which amino acid changes in the LMP1 carboxy terminus lead to a loss of recognition by the S12 antibody (Hu et al., 1991; Miller et al., 1994) . The results presented here suggest that the lack of C15-LMP1 protein recognition by the S12 monoclonal antibody is due to amino acid changes within the repeat sequence in the carboxy terminus of C15-LMP1 (Figures 1 and 3) .
Activation of a kB-dependent reporter gene by the C15-LMP1 and B95/C15 chimeric proteins Each of the LMP1 proteins was analysed for NF-kB activation using a reporter construct (kB-CAT) that contains the kB sites from the HIV-LTR. The B95-LMP1 protein activated NF-kB 6.2-fold over vector control (Figure 4) . The C15 derived LMP1 protein consistently activated NF-kB more strongly (11.6-fold over vector control) than the B95 derived LMP1 protein. This eect was shown to be speci®c for NFkB as the same construct lacking the kB sites from the HIV-LTR (TATA-CAT) was unresponsive to LMP1 (data not shown). To localize the region of the C15-LMP1 protein which is responsible for this increased transactivation, the chimeric LMP1 molecules were analysed for NF-kB activation. The chimeric construct which contained the amino terminal 181 amino acids from C15-LMP1 (C15/B95) was a stronger activator of NF-kB (13.8-fold over vector control) than the chimera (B95/C15) which contained the 181 amino terminal amino acids from the B95-LMP1 sequence (4.6-fold over vector control). The levels of LMP1 expression from the various constructs were approximately equal, therefore the increased activation of NK-kB by the C15-LMP1 protein could not be explained by dierent levels of LMP1 expression (Figures 3 and 4) . Immunoblots were routinely stained with Ponceau S to demonstrate equal loading of protein. Therefore, the increased NF-kB activity detected with the C15-LMP1
CS1-4 (1:100) S12 (1:10) Figure 3 Expression of the C15 derived LMP1 and B95/C15 chimeric proteins. Immunoblot analysis was performed to analyse expression of the LMP1 proteins. Cells were transfected with the plasmid indicated above each lane. Parallel blots were probed with the CS1-4 (1 : 100 dilution) and S12 (1 : 10 dilution) anti-LMP1 mAbs. In con®rmation of previous observations, only the LMP1 proteins containing the B95 C-terminus were recognized by the S12 mAB, while all LMP1 proteins were recognized by the CS1-4 mAB. The CB5 (strain B95) infected LCL was used as a positive control for LMP1 expression recognized by both antibodies Figure 4 Activation of a NF-kB reporter gene by the C15 derived LMP1 and B95/C15 chimeric proteins. LMP1 expression constructs (2 mg) encoding B95 or C15 derived LMP1 proteins, as well as chimeric proteins were transfected into C33A cells along with a kB-CAT reporter construct (1 mg). kB-CAT contains the kB sites from the HIV-LTR linked to a minimal TATA box containing promoter. Cells were harvested 48 h after transfection and CAT activity was quantitated as described in the Materials and methods. The results are shown as fold activation over vector (pcDNA3) transfected control. Error bars are shown and represent +s.e.m. The data represents four independent experiments performed in duplicate must be due to amino acid changes in the transmembrane domain of LMP1. The transmembrane domain is essential for LMP1 function but does not interact with the signaling molecules which interact with LMP1. The ®ve amino acid changes within the transmembrane domains could contribute to the increased NF-kB activation by altering the aggregation of LMP1 in the cell membrane, which is a property of LMP1 that is essential for its function. A noteworthy point is that changes in the cytoplasmic domain of C15-LMP1 did not eect NF-kB activation by LMP1. In particular, similar to other wildtype LMP1 isolates, deletion of amino acids 343 ± 352 did not aect this signaling property of LMP1 (Rothenberger et al., 1997) .
Analysis of NF-kB complexes in the nucleus of cell lines expressing the C15-LMP1 and B95/C15 chimeric proteins
To further evaluate the enhanced activation of NF-kB by the C15-LMP1 protein compared to the B95-LMP1 protein, electrophoretic mobility shift assays (EMSA) were performed. C33A cell lines were established which expressed either the B95-LMP1 or C15-LMP1 protein, or one of the chimeric proteins described above. Nuclear extracts were prepared from these cell lines and assayed for the presence of NF-kB containing complexes by EMSA. Since the NF-kB complexes induced by LMP1 have been previously characterized using the Class I MHC kB sites and experiments comparing NF-kB binding activities using either the Class I MHC or HIV-LTR kB sites yielded comparable results, the kB sites from the Class I MHC promoter was used in the experiments described here (Paine et al., 1995; Cheshire and Baldwin, 1997) . In agreement with the kB-dependent reporter assays, the C15-LMP1 protein induced higher levels of nuclear NF-kB components when compared to the B95-LMP1 protein ( Figure 5 ). Both LMP1 proteins induced the same three NF-kB complexes, but C15-LMP1 induced higher levels of each individual complex. The presence of a protein in nuclear extracts which binds non-speci®cally to the probe is indicated by an arrow and revealed equal concentrations of nuclear proteins in the mobility shift reaction. The exposure shown in Figure 5 was chosen to highlight the dierences in activated complexes between the various cell lines and although complex 2 is not clearly visible in all lanes, it is present on longer exposures (data not shown). The components of these complexes were identi®ed previously and con®rmed in this study (Paine et al., 1995) . Supershift analyses indicate that Complex 3 contains p50/p50 homodimers, Complex 2 contains p50/p52 heterodimers, and Complex 1 contains p52 and p65 as well as other unknown components (data not shown). Analysis of chimeric LMP1-proteins also con®rmed the ®nding that the amino terminal 181 amino acids of the C15-LMP1 protein confer the increased signaling capacity since the chimera which contains the C15 amino terminus (C15/B95) induced much higher levels of the NF-kB complexes when compared with either the full-length B95-LMP1 protein or the chimera which contains the amino terminal 181 amino acids of B95-LMP1 (B95/C15). These data con®rm that amino acid changes present in the transmembrane domain of C15-LMP1 confer increased signaling, and that amino acid changes in the carboxy terminal region, as well as deletion of amino acids 343 ± 352, do not aect the increased ability of C15-LMP1 to activate NF-kB.
Induction of EGFR expression by the C15-LMP1 and B95/C15 chimeric proteins
Previous studies demonstrate that LMP1 induces expression of the EGFR through a mechanism which is distinct from NF-kB activation alone. Speci®cally, a LMP1 protein deleted for the distal NF-kB activation domain (LMP1-D232 ± 386), but that retains the TRAF interaction domain, is capable of inducing high levels of EGFR expression (Miller et al., 1997) . This induction of EGFR expression by LMP1 provides the only known manifestation of TRAF signaling that does not re¯ect NF-kB activation. To determine if the increased signaling capability of the C15-LMP1 extends to LMP1-aected pathways other than NFkB activation, the eect of C15-LMP1 on EGFR induction was investigated. Cytoplasmic extracts from the cell lines expressing either the B95-LMP1 or the C15-LMP1 proteins, or one of the chimeras were assayed for EGFR expression by immunoblot ( Figure  6a ). The C15-LMP1 protein induced higher levels of the EGFR than did the B95-LMP1 protein. The Non-Specific Figure 5 EMSA analysis of NF-kB complexes in stable cell lines expressing the C15 derived LMP1 and B95/C15 chimeric proteins. Mobility shift analysis was performed with 10 mg of nuclear extracts isolated from the indicated cell lines. The 32 P labeled probe contains the NF-kB site from the MHC class I promoter. The three speci®c NF-kB containing complexes induced by LMP1 are indicated by arrows. The non-speci®c band represents a nuclear protein which binds non-speci®cally to the mobility shift probe and demonstrates equal loading of nuclear extracts from the individual cell lines increased eect of the C15-LMP1 protein on induction of the EGFR, like that of NF-kB, was localized to the amino terminal 181 amino acids of the C15-LMP1 isolate. The chimeric protein which contained the amino terminal 181 amino acids from the C15-LMP1 (C15/B95) induced higher levels of the EGFR than either the B95-LMP1 protein or the chimera containing the amino terminal 181 amino acids from B95-LMP1 (B95/C15). The same extracts used in Figure 6a were analysed for LMP1 expression by immunoblot using the CS1-4 monoclonal antibody (Figure 6b) . Although the LMP1 proteins with the C15 carboxy terminus pcLMP1(C15) and pcLMP1(B95/C15), were detected at slightly lower levels, the enhanced EGFR expression due to the amino terminal 181 amino acids of C15-LMP1 cannot be attributed to diering levels of LMP1 since both pcLMP1(C15) and pcLMP1(C15/B95) induced equal levels of the EGFR. These data reveal that both EGFR induction and NF-kB activation are increased with the C15-LMP1 isolate and indicate that amino acid changes in the hydrophobic transmembrane domains increase LMP1 signaling in general.
Discussion
EBV is essentially ubiquitous in the human population, however, in some geographic regions viral infection is associated with a dramatic increase in the development of malignancies such as NPC. Dierences in EBV strains circulating in regions endemic for NPC such as Southern China, Alaska, and the Mediterranean could possibly contribute to the increased frequency of the disease. EBV gene expression in NPC is limited to EBNA1, LMP1, and LMP2, therefore the contribution of EBV sequence variation to the development of NPC is likely to reside within these genes (Fahraeus et al., 1988; Young et al., 1988; Abdel-Hamid et al., 1992; Busson et al., 1992) .
The contribution of sequence variation towards alteration in the function of viral proteins has been demonstrated with other viruses. For example, sequence variation in viral gene products is important in the development of malignancies associated with the Human Papilloma Virus (HPV) (Howley, 1996) . HPV types 16 and 18 are high risk viruses often associated with cervical carcinoma, while HPV types 6 and 11 are low risk viruses often associated with benign cervical lesions and genital warts (Howley, 1996) . Strain dierences in the HPV oncoproteins E6 and E7 dramatically in¯uence their biological activities. Only the E6 and E7 proteins from high risk HPV isolates eciently bind to the cellular p53 and pRB proteins; functions which are critical for the transforming properties of HPV (Scheener et al., 1990; Howley, 1996) .
Recent studies have described considerable sequence variation within the gene for the EBV encoded LMP1 protein (Hu et al., 1991 (Hu et al., , 1993 Chen et al., 1992; Miller et al., 1994) . The dierences detected between LMP1 isolates do not correlate directly with type 1 or type 2 EBV or with geographic location (Miller et al., 1994) . Although this variation in LMP1 sequence does not segregate with geographic location or EBV subtype, some alterations were found at high frequency in areas endemic for NPC. For instance, speci®c deletions of amino acids 343 ± 352 and a cluster of mutations (amino acids 13, 17, 46 and 84) were found in most isolates from Southern China (Miller et al., 1994) .
In this study the NPC derived C15-LMP1 gene was cloned into an expression vector and analysed for its ability to activate NF-kB and to induce EGFR expression. C15 is an NPC tumor obtained from the Mediterranean region, which like Southern China has an increased risk for NPC development. The C15-LMP1 gene is deleted for amino acids 343 ± 352 which are commonly deleted in the Asian LMP1 isolates, but does not contain the cluster of mutations detected in the amino terminal region of isolates from the Asian populations.
The LMP1 expression constructs were functional and the proteins were expressed at nearly equal levels. In agreement with observations made using extracts from a C15 NPC tumor, the C15 derived LMP1 protein was not detected with the S12 monoclonal antibody (Young et al., 1988) . The sequence analysis of the C15-LMP1 gene suggests that the lack of recognition of the C15-LMP1 protein by the S12 monoclonal antibody is due to mutations in the repeat region in the carboxy terminus.
The C15-LMP1 isolate activated NF-kB-dependent gene expression to greater levels than the B95-LMP1 isolate in kB-dependent reporter gene assays, and the enhanced eect of the C15-LMP1 was localized to the amino terminal 181 amino acids. This suggests that an amino acid change(s) in the transmembrane domain region of the C15-LMP1 confers the enhanced ability to activate NF-kB. The proteins are expressed at nearly equal levels, so it is unlikely that the level of LMP1 protein expression contributes to the enhanced NF-kB activation observed with the C15-LMP1 protein.
Analysis of nuclear NF-kB complexes by EMSA revealed that both B95-LMP1 and C15-LMP1 activate the same complexes, although the C15-LMP1 expressing cells contain an increased amount of each complex. This reveals that the C15-LMP1 protein does not activate distinct NF-kB complexes, rather the C15-LMP1 protein causes a general increase in nuclear NF-kB complexes. Similarly, the C15-LMP1 protein induced higher levels of the EGFR and this enhanced eect was localized to the amino terminal 181 amino acids of LMP1. The data indicate that sequence changes in the transmembrane domains of the C15-LMP1 protein aect signaling from both the TRAF domain resulting in enhanced EGFR induction, and the distal domain resulting in enhanced NF-kB activation.
Although the amino acid changes in C15-LMP1 which contribute to enhanced NF-kB activation and EGFR induction do not reside within the LMP1 amino terminus or within the carboxy terminal signaling domains, they do reside in the region of LMP1 that is essential for proper membrane localization and clustering (Liebowitz et al., 1986 (Liebowitz et al., , 1992 Huen et al., 1995; Mitchell and Sugden, 1995) . These changes could aect the interaction between individual LMP1 molecules clustered in the membrane, or could possibly aect the interactions of LMP1 with other cellular proteins in the membrane.
Previous studies by several groups have suggested that deletions of amino acids 343 ± 352 within LMP1 increases its transformation potential in rodent ®broblasts Li et al., 1996) . Although it cannot be discounted that deletion of amino acids 343 ± 352 may in¯uence rodent ®broblast transformation, the experiments presented here suggest that deletion of amino acids 343 ± 352 does not in¯uence speci®c molecular signaling properties of LMP1, including NF-kB activation and EGFR induction. In conclusion, the data presented in this study suggest that sequence variation present in wildtype isolates of LMP1, like those isolated from NPC tumors, aects the function of the LMP1 protein.
Although not as dramatic as the dierences detected in the function of the HPV E6 and E7 proteins derived from high risk vs low risk viruses, changes in the amino acid sequence of the EBV LMP1 proteins from high risk, endemic areas, may contribute to the function of LMP1 in inducing growth transformation in tumors like NPC.
Materials and methods
Cell lines and nude mouse passaged NPC tumors
C33A epithelial cells (ATCC, HTB 31) derived from a cervical carcinoma were grown at 378C in DMEM-H supplemented with 10% FCS and antibiotics. C33A cells were routinely grown in 100 mm cell culture dishes and split 1 : 5 three times weekly. CB5 (B95) is an EBV immortalized lymphoblastoid cell line (LCL) established in the laboratory by infection of cord blood lymphocytes with B95-8 virus. CB5 (B95) cells were maintained in suspension in RPMI supplemented with 10% FCS and antibiotics. C15 is an EBV-positive NPC tumor which is passaged serially in nude mice. C33A cells expressing various LMP1 proteins were obtained by selection in 600 mg/ml G418 (Geneticin, Gibco-BRL) following transfection with an expression construct containing the LMP1 gene. Brie¯y 5610 5 cells were seeded in 60 mm dishes and lipofected according to the manufacturer's speci®cations with 5 mg of DNA (Lipofectin, Gibco-BRL). Transfected cells were fed with fresh media 24 h post-transfection and 48 h post-transfection the media was replaced with fresh media containing G418. Cell lines were created by pooling450 G418 resistant colonies.
Plasmids and expression vectors
The LMP1 cDNA derived from the B95 strain of EBV was a kind gift of Elliott Kie. The B95 derived cDNA contains 43 nucleotides upstream of the translation start site and 1155 nucleotides downstream of the stop codon. The LMP1 cDNA derived from the C15 (NPC) strain of EBV was constructed by fusing two cDNAs (C31 and C103) obtained from a C15 cDNA library at a unique BsaBI site in the LMP1 gene (Gilligan et al., 1990) . The unique BsaBI site in the LMP1 cDNA is located at amino acid 181 of the LMP1 protein. The C15 derived cDNA also contains 243 nucleotides upstream of the translation start site and the same 3' untranslated sequence described above for the B95 derived cDNA. Automated sequence analysis of the complete C15-LMP1 cDNA revealed several nucleotide changes resulting in amino acid changes which were not detected previously using standard sequencing techniques (Figure 1 ). The complete C15-LMP1 sequence is reported in GenBank (Accession number AF023171). Chimeric LMP1 cDNAs containing parts of the B95 and C15 LMP derived cDNAs were created by fusing the two dierent cDNAs at the BsaBI site. This creates LMP1 cDNAs with amino acids 1 ± 181 of either the B95 or C15 cDNA fused to amino acids 182 ± 386 of either the C15 or B95 cDNAs. The pcDNA3 eukaryotic expression vector (Invitrogen) which contains the CMV immediate early promoter and polyadenylation sequence from the bovine growth hormone was used for the LMP1 expression constructs. The LMP1 cDNAs were subcloned into the EcoRI site of pcDNA3. The reporter construct, kB-CAT (generous gift of B Stein), contains two copies of the kB site from the HIV-LTR (7105/775) cloned upstream of the TATA region from the Xenopus albumin promoter linked to the CAT gene (Schorpp et al., 1988; Stein et al., 1989) .
Transfections and CAT assays
Transfections of C33A epithelial cells were carried out with 5610 5 cells per 60 mm dish using Lipofectin according to the manufacturer's speci®cations (Gibco-BRL). To evaluate protein expression, 5 mg of each plasmid was transfected, 48 h later the cells were harvested and analysed by immunoblot. In order to evaluate the ability of each protein to activate NF-kB, 1 mg of reporter plasmid (kB-CAT) was transfected with 2 mg of eector plasmid (LMP1 plasmids derived from B95 and C15 or B95/C15 and C15/B95 chimeras). Four independent experiments were performed in duplicate to control for transfection eciency. Cells were fed with serum containing media 24 h after transfection, and 24 h after feeding cells were washed in PBS, resuspended in 0.25 M Tris-HCl and lysed by repeated cycles of freeze/thaw. Extracts were normalized for protein concentration and assayed for CAT activity as described (Gorman et al., 1982; Stein et al., 1989) . Acetylated and non-acetylated forms of 14 Cchloramphenicol were separated by thin layer chromatography and analysed on a Phosphorimaging screen (Molecular Dynamics).
Nuclear and cytoplasmic extracts
Cell lines expressing various derivatives of LMP1 were seeded in 100 mm dishes and were harvested for extract preparation when the cells were *75% con¯uent. Extracts were prepared using modi®cation of a previously described procedure (Cheshire and Baldwin, 1997) . Brie¯y, cells were washed once with ice cold phosphate-buered saline (PBS), scraped from the dishes, collected in microcentrifuge tubes, and lysed for 3 min on ice in ®ve pellet volumes of cytoplasmic extraction buer (10 mM HEPES pH 7.6, 60 mM KCl, 1 mM EDTA, 0.1% NP-40, 1 mM DTT, 1 mM PMSF and 2.5 mg/ml each of aprotinin, leupeptin and pepstatin). Nuclei were collected (1500 r.p.m., 48C, 5 min) and the supernatants containing the cytoplasmic fraction were transferred to fresh tubes. Nuclei were washed with 300 ml of cytoplasmic extraction buer without NP-40, collected as before, and lysed in three pellet volumes of nuclear extraction buer (20 mM Tris pH 8.0, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM PMSF, 25% glycerol, and 2.5 mg/ml each of aprotinin, leupeptin and pepstatin). The ®nal salt concentration was adjusted to *400 mM with NaCl, and nuclear pellets were vortexed and incubated on ice for 10 min. Cytoplasmic and nuclear extracts were cleared (14 000 r.p.m., 48C, 10 min) and transferred to fresh tubes. Glycerol was added to the cytoplasmic extracts to a ®nal concentration of 20% and protein concentrations were determined with the Bio-Rad protein assay dye reagent.
Immunoblot analysis
Cytoplasmic extracts (100 mg) were mixed with equal volumes of 26 sample buer, boiled for 10 min, separated on 8% SDS-polyacrylamide gels and transferred to supported nitrocellulose ®lters (Schleicher and Schuell) using a BIO-RAD trans-blot wet electrophoretic transfer apparatus. Filters were stained with Ponceau S stain to ensure equal loading of protein in all lanes. Non-speci®c reactivity was blocked by incubation in Tris-buered saline containing 0.1% Tween 20 and 5% non-fat dried milk (BLOTTO). For the detection of LMP1, the S12 monoclonal antibody (kindly provided by David A Thorley-Lawson) was used at a 1 : 10 dilution in BLOTTO, or the CS1-4 monoclonal antibody (DAKO) was used at a 1 : 100 dilution in BLOTTO. A rabbit antiserum raised against the carboxy terminal 100 amino acids of the EGFR fused to GST (ERCT) (kindly provided by H Shelton Earp) was used at a 1 : 1500 dilution in BLOTTO for the detection of the EGFR. Appropriate secondary anti-mouse or anti-rabbit antibodies conjugated to horseradish peroxidase (Amersham) were used at a dilution of 1 : 2000 in BLOTTO to detect bound primary antibody. Reactive proteins were detected by incubation of washed ®lters in the enhanced chemiluminescence system (ECL, Amersham) followed by exposure to autoradiographic ®lm.
Electrophoretic mobility shift assays
Nuclear extracts (10 mg) were incubated for 15 min at room temperature with a 32 P-labeled probe containing a kB site from the Class I MHC promoter (5'-CAGGGCTGGG-GATTCCCCATCTCCACAGTTTCACTTC-3') in binding buer (10 mM Tris pH 7.7, 50 mM NaCl, 0.5 mM EDTA, 1 mM DTT and 10% glycerol) with 2 mg Poly (dI/dC).Poly (dI/dC) (Pharmacia Biotech) Sharp, 1987, 1988; Haskill et al., 1991; Scheinman et al., 1993) . Complexes were separated on 5% polyacrylamide gels in high ionic strength, Tris-glycine-EDTA buer (25 mM Tris, 190 mM glycine, and 1 mM EDTA), dried, and subjected to autoradiography. For supershift experiments, 1 ± 5 ml of rabbit polyclonal antibodies against the NF-kB subunits p50 (sc-114, Santa Cruz Biotechnology), p52 (#100-4185, Rockland), or p65 (#100-4165, Rockland) were incubated with nuclear extracts for 15 min prior to the addition of Poly (dI/dC).Poly (dI/dC) and 32 P labeled probe. Complexes were then analysed as described.
